GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Return-on-Tangible-Asset

Vivos (RDGL) Return-on-Tangible-Asset : -218.98% (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Vivos Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vivos's annualized Net Income for the quarter that ended in Sep. 2024 was $-3.30 Mil. Vivos's average total tangible assets for the quarter that ended in Sep. 2024 was $1.51 Mil. Therefore, Vivos's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 was -218.98%.

The historical rank and industry rank for Vivos's Return-on-Tangible-Asset or its related term are showing as below:

RDGL' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -48143.75   Med: -2781.63   Max: 4566.3
Current: -195.63

During the past 13 years, Vivos's highest Return-on-Tangible-Asset was 4566.30%. The lowest was -48143.75%. And the median was -2781.63%.

RDGL's Return-on-Tangible-Asset is ranked worse than
94.35% of 868 companies
in the Medical Devices & Instruments industry
Industry Median: -2.435 vs RDGL: -195.63

Vivos Return-on-Tangible-Asset Historical Data

The historical data trend for Vivos's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Return-on-Tangible-Asset Chart

Vivos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,366.67 -194.91 -196.58 -146.28 -172.68

Vivos Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -159.19 -270.95 -149.47 -127.66 -218.98

Competitive Comparison of Vivos's Return-on-Tangible-Asset

For the Medical Devices subindustry, Vivos's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Vivos's Return-on-Tangible-Asset falls into.



Vivos Return-on-Tangible-Asset Calculation

Vivos's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-2.895/( (1.743+1.61)/ 2 )
=-2.895/1.6765
=-172.68 %

Vivos's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-3.3/( (1.77+1.244)/ 2 )
=-3.3/1.507
=-218.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data.


Vivos  (OTCPK:RDGL) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Vivos Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Vivos's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Business Description

Traded in Other Exchanges
N/A
Address
719 Jadwin Avenue, Richland, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Executives
Michael K Korenko officer: INTERIM CEO AND PRESIDENT 6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack officer: Interim CFO 114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle 10 percent owner 505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak director 9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement director 12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff officer: Chief Financial Officer 206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust 10 percent owner 909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff director, 10 percent owner, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford director, 10 percent owner 6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell director, 10 percent owner 6208 W OKANOGAN AVE, KENNEWICK WA 99336

Vivos Headlines

From GuruFocus

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 06-21-2022

Vivos Inc. Provides Intellectual Property Protection Update

By PurpleRose PurpleRose 07-11-2022

Vivos Inc. Provides 2021 Recap and Outlines 2022 Objectives

By GuruFocusNews GuruFocusNews 01-24-2022

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 06-11-2022

Vivos Inc Initiates Isopet� Therapy in Horses

By Marketwired Marketwired 06-24-2021

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 06-01-2022

Vivos Inc. Provides Intellectual Property Protection Update

By GuruFocusNews GuruFocusNews 07-01-2022